Abstracts tagged "meta-analysis and thrombosis"

Abstract Number: 2459 • 2012 ACR/ARHP Annual Meeting
Efficacy of Aspirin for the Prevention of the First Thrombo-Embolic Events in Patients with Antiphospholipid Antibodies: A Metanalysis of Literature Data
Laurent Arnaud¹, Alexis Mathian², Amelia Ruffatti³, Maria Tecktonidou⁴, Ricard Cervera⁵, Ricardo Forastiero⁶, Vittorio Pengo⁷, Marc Lambert⁸, Stephane Zuily⁹, Denis Wahl⁹ and Zahir Amoura¹, ¹Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ³Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy, ⁴First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ⁵Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain, ⁶Favaloro University, Argentina, ⁷Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ⁸Medecine Interne Lilloise, Internal Medicine University Lille Hospital, Lille, Lille, France, ⁹Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy University Hospital, Université de Lorraine & INSERM U961, Vandoeuvre-Les-Nancy, France
Background/Purpose: Whether aspirin is needed in patients with antiphospholipid antibodies (aPL+) for prevention of a first thrombotic event is controversial. The aim of this metaanalysis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].